Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study

Overview of attention for article published in AIDS Research and Therapy, August 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news: 1 news outlet

patent: 1 patent

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 61 Mendeley

Summary News Patents Dimensions citations

So far, Altmetric has seen 1 patent that references this research output.

A PROTEASE INHIBITOR REGIMEN FOR TREATING SUBJECTS INFECTED WITH HIV

Application WO-2021180963-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.